Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism.
SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis-osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-alpha) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-alpha blockade therapy.
Sabugo
Francisca
F
Rheumatology Section, Department of Medicine, Clinical Hospital, University of Chile, Independencia, Santiago, Chile.
Liberman
Claudio
C
Niedmann
Juan Pablo
JP
Soto
Lilian
L
Cuchacovich
Miguel
M
D020083:Acquired Hyperostosis Syndrome / Q000188:drug therapy*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy*; D000069285:Infliximab; D008297:Male; D012074:Remission Induction; D013974:Thyroxine / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D013974:Thyroxine